|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
The qRT-PCR data confirmed that mRNA levels of EGR1, FOS, and FOSB all were decreased in HCC tissues.
|
30228980 |
2018 |
|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Liver-enriched activator protein 1 as an isoform of CCAAT/enhancer-binding protein beta suppresses stem cell features of hepatocellular carcinoma.
|
29731667 |
2018 |
|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells.
|
25526895 |
2015 |
|
Liver carcinoma
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Among them, one novel SNP was found in activator protein-1 (AP2), a transcription factor binding site (-483 A to C) that may be associated with the susceptibility to HCC (P = 0.012) but no associations were found for other observed variations.This mutation could be tumor-specific.
|
24659263 |
2014 |
|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Our analysis indicated that several differentially co-express genes might play crucial roles in HCC development, including NA3C2, AHR, MYC, FOXO1 and FOSB.
|
22913147 |
2012 |
|
Liver carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the expression of KITENIN and AP-1 target genes at mRNA levels by RT-PCR in human HCC tissues and paired normal hepatic mucosa of the same patients taken by surgery.
|
21473287 |
2011 |
|
Liver carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Our results reveal a new AP-1 site within the TRAIL promoter functionally involved in TGF-beta-induced TRAIL expression and apoptosis in hepatomas and thus provide evidence for the underlying mechanism by which TGF-beta might regulate cell death in liver cancer.
|
18644981 |
2008 |
|
Liver carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our findings demonstrated for the first time that acetaldehyde activated NF-kappaB and AP-1 activities via IkappaB, JNK/beta-TrCP, and p38 signaling pathways, resulting in MMP-9 gene expression and hepatocarcinoma cells invasion.
|
17543481 |
2007 |
|
Malignant neoplasm of lung
|
0.320 |
Biomarker
|
disease |
CTD_human |
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.
|
27935865 |
2017 |
|
Malignant neoplasm of lung
|
0.320 |
Biomarker
|
disease |
BEFREE |
Interleukin-7 up-regulates cyclin D1 via activator protein-1 to promote proliferation of cell in lung cancer.
|
21847632 |
2012 |
|
Malignant neoplasm of lung
|
0.320 |
Biomarker
|
disease |
BEFREE |
Our data, thus, point to a histiotype-related mechanism of recruitment among AP-1 proteins which may have bearings on the fate of lung cancer development.
|
9662339 |
1998 |
|
Epilepsy
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, geniposide significantly suppressed the protein expression of activator protein 1, increased the activation of Akt and increased the protein expression of GSK-3β and PI3K in epilepsy mice (all P<0.01).
|
29399113 |
2018 |
|
Liver neoplasms
|
0.310 |
Biomarker
|
group |
BEFREE |
Our data suggest a critical role for KDM3A in the PI3K/AP-1 oncogenic axis and propose a novel strategy for inhibition of KDM3A against liver tumor development under PI3K pathway activation.
|
28692045 |
2017 |
|
Cocaine Abuse
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Thus, we provide the first evidence of FosB gene expression in human HPC and PFC in these psychiatric disorders, and in light of recent findings demonstrating the critical role of HPC ΔFosB in rodent models of learning and memory, these data suggest that reduced ΔFosB in HPC could potentially underlie cognitive deficits accompanying chronic cocaine abuse or depression.
|
27494187 |
2016 |
|
Liver neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
[Exploration of Epigenetic Changes and DNA Methylation Markers Associated with Liver Tumors Induced by Inorganic Arsenite Exposure in Mice].
|
26411935 |
2015 |
|
Malignant neoplasm of liver
|
0.310 |
Biomarker
|
disease |
CTD_human |
[Exploration of Epigenetic Changes and DNA Methylation Markers Associated with Liver Tumors Induced by Inorganic Arsenite Exposure in Mice].
|
26411935 |
2015 |
|
Cocaine Abuse
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Increased impulsivity during withdrawal from cocaine self-administration: role for DeltaFosB in the orbitofrontal cortex.
|
18539927 |
2009 |
|
Cocaine Abuse
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Overexpression of DeltaFosB is associated with attenuated cocaine-induced suppression of saccharin intake in mice.
|
19331462 |
2009 |
|
Cocaine Abuse
|
0.310 |
Biomarker
|
disease |
CTD_human |
Increased impulsivity during withdrawal from cocaine self-administration: role for DeltaFosB in the orbitofrontal cortex.
|
18539927 |
2009 |
|
Cocaine Abuse
|
0.310 |
Biomarker
|
disease |
CTD_human |
Overexpression of DeltaFosB is associated with attenuated cocaine-induced suppression of saccharin intake in mice.
|
19331462 |
2009 |
|
Malignant neoplasm of liver
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Our results reveal a new AP-1 site within the TRAIL promoter functionally involved in TGF-beta-induced TRAIL expression and apoptosis in hepatomas and thus provide evidence for the underlying mechanism by which TGF-beta might regulate cell death in liver cancer.
|
18644981 |
2008 |
|
Cocaine Abuse
|
0.310 |
Therapeutic
|
disease |
CTD_human |
DeltaFosB induction in orbitofrontal cortex mediates tolerance to cocaine-induced cognitive dysfunction.
|
17898221 |
2007 |
|
Cocaine Abuse
|
0.310 |
Biomarker
|
disease |
CTD_human |
DeltaFosB induction in orbitofrontal cortex mediates tolerance to cocaine-induced cognitive dysfunction.
|
17898221 |
2007 |
|
Epilepsy
|
0.310 |
Biomarker
|
disease |
CTD_human |
Impaired activation of CA3 pyramidal neurons in the epileptic hippocampus.
|
16391389 |
2005 |